Showing results (541-550 of 667) with videos related to

Sort By:
Pageof 67
Cell|April 2, 1999
Prion protein of 106 residues creates an artifical transmission barrier for prion replication in transgenic miceS Supattapone, P Bosque, T Muramoto, et al.
Leukemia|September 10, 2005
A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinibL C Crossman, T O'Hare, T Lange, et al.
BMC Cancer|May 6, 2022
A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumorMaria A Pantaleo, Michael C Heinrich, Antoine Italiano, et al.
Blood|December 17, 2008
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patientsJeffrey W Tyner, Heidi Erickson, Michael W N Deininger, et al.
The Journal of Biological Chemistry|October 31, 2002
SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130Ute Lehmann, Jochen Schmitz, Manuela Weissenbach, et al.
Experimental Hematology|January 16, 1998
Expression of the Fanconi anemia group C gene in hematopoietic cells is not influenced by oxidative stress, cross-linking agents, radiation, heat, or mitotic inhibitory factorsP A Tower, T A Christianson, S T Peters, et al.
Cancer Research|July 31, 2010
MET receptor sequence variants R970C and T992I lack transforming capacityJeffrey W Tyner, Luke B Fletcher, Ellen Q Wang, et al.
Blood|July 1, 1996
Germ cell defects and hematopoietic hypersensitivity to gamma-interferon in mice with a targeted disruption of the Fanconi anemia C geneM A Whitney, G Royle, M J Low, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2013
Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancerChristine M Barnett, Michael C Heinrich, Jeong Lim, et al.
Cancer Research|June 3, 2005
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutantsThomas O'Hare, Denise K Walters, Eric P Stoffregen, et al.
Pageof 67